menu
    • menu
    [{"orgOrder":0,"company":"Caplin Steriles","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Milrinone","moa":"PDE3","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Caplin Steriles","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Caplin Steriles \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Caplin Steriles \/ Not Applicable"},{"orgOrder":0,"company":"Caplin Steriles","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Milrinone","moa":"PDE3","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Caplin Steriles","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Caplin Steriles \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Caplin Steriles \/ Not Applicable"},{"orgOrder":0,"company":"Baker Institute","sponsor":"Hyloris Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"AUSTRALIA","productType":"Small molecule","year":"2021","type":"Acquisition","leadProduct":"Milrinone","moa":"PDE3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Baker Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Extended Release Capsule","sponsorNew":"Baker Institute \/ Hyloris Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Baker Institute \/ Hyloris Pharmaceuticals"}]

    Find Clinical Drug Pipeline Developments & Deals for Milrinone Lactate

    Menu

    Milrinone Lactate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Baker Institute

                            Country arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Baker Institute

                            Country arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Milrinone

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase I/ Phase II

                            Sponsor : Hyloris Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Hyloris Expands Cardiovascular Pipeline with Breakthrough Extended-Release Milrinone Capsule in Late-Stage Hea...

                            Details : Under the terms of the agreement, Hyloris will be responsible for the development, manufacturing, regulatory affairs, and commercialisation of CRD-102. CRD-102 is a novel, patented, extended-release Milrinone capsule.

                            Brand Name : CRD-102

                            Molecule Type : Small molecule

                            Upfront Cash : $0.1 million

                            October 08, 2021

                            Lead Product(s) : Milrinone

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Hyloris Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Caplin Steriles

                            India arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Caplin Steriles

                            India arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Milrinone

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Caplin Steriles Gets US FDA Approval for Generic Bloxiverz Injection

                            Details : Caplin Steriles has been granted final approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) neostigmine methylsulfate injection USP, 5 mg/10 mL (0.5 mg/mL) and 10 mg/10 mL (1 mg/mL).

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 22, 2021

                            Lead Product(s) : Milrinone

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Caplin Steriles

                            India arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Caplin Steriles

                            India arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Milrinone

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Caplin Steriles Receives Final USFDA Approval for Milrinone Lactate Injection

                            Details : Caplin Steriles has been granted final approval from the USFDA for its ANDA Milrinone Lactate Injection USP, 10 mg/10 mL, 20 mg/20 mL, 50 mg/50 mL, Single-dose vial presentation, a generic therapeutic equivalent version of, PRIMACOR Injection, 1 mg/mL, o...

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 19, 2021

                            Lead Product(s) : Milrinone

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth